KAEL–GemVax: TeloVac Becomes World’s Largest Ever Pancreatic Cancer Vaccine Trial

SEOUL, South Korea & OSLO, Norway--(BUSINESS WIRE)--KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that it had been officially notified by the independent Data Monitoring Committee that over 1000 patients have been enrolled in the TeloVac Study, making it the world’s largest ever pancreatic cancer vaccine trial. This also means that the TeloVac study is on course to finish recruitment in August 2011, with results expected in late 2012.

Back to news